JACC Cardiovasc Interv

SGLT2 inhibitors may slow aortic stenosis progression

March 7, 2025

Study details: This multicenter observational study utilized retrospective electronic medical record data from the Yale New Haven Health System, spanning January 2016 to September 2022. The study followed 11,698 patients with native aortic valve sclerosis or nonsevere aortic stenosis (AS), comparing 458 patients on SGLT2 inhibitors to 11,240 not on the medication.

Results: Over 5 years of follow-up, patients on SGLT2 inhibitors were less likely to progress to severe AS (hazard ratio [HR], 0.61; 95% confidence interval, 0.39-0.94; P = 0.03), with a progressively lower risk among patients on SGLT2 inhibitors for >3, 6, and 12 months (HRs: 0.54, 0.48, and 0.27, respectively).

Clinical impact: SGLT2 inhibitors may offer a novel therapeutic approach to slowing AS progression. Further prospective studies are needed to confirm these results and explore long-term benefits.

Source:

Shah T, et al. (2025, February 19). JACC Cardiovasc Interv. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. https://pubmed.ncbi.nlm.nih.gov/39985508/